What are the recommended TNF‑α inhibitors, their dosing regimens and administration frequencies, and their brand names (with generic names)?

TNF Inhibitor Recommendations: Dosing and Brand Names

For moderate-to-severe psoriasis, the recommended TNF inhibitors are adalimumab (Humira) 80 mg initially then 40 mg every 2 weeks, infliximab (Remicade) 5 mg/kg IV at weeks 0,2,6 then every 8 weeks, and etanercept (Enbrel) 50 mg subcutaneously twice weekly for 12 weeks then once weekly—with adalimumab and infliximab generally preferred over etanercept for superior efficacy. 1

Primary TNF Inhibitors with Complete Dosing

Adalimumab (Humira)

• Induction: 80 mg subcutaneous injection at week 0, followed by 40 mg at week 1
• Maintenance: 40 mg subcutaneous injection every 2 weeks
• Strength of recommendation: Grade A for psoriasis 1
• Can be dose-escalated to 40 mg weekly in patients with inadequate response 2

Infliximab (Remicade)

• Induction: 5 mg/kg IV infusion at weeks 0,2, and 6
• Maintenance: 5 mg/kg IV infusion every 8 weeks
• Strength of recommendation: Grade A for psoriasis 1
• Can be dose-escalated up to 10 mg/kg and/or administered as frequently as every 4 weeks for better disease control 1
• Reserved for very severe disease or when other biologics have failed 2

Etanercept (Enbrel)

• Induction: 50 mg subcutaneous injection twice weekly for 12 consecutive weeks
• Maintenance: 50 mg subcutaneous injection once weekly
• Strength of recommendation: Grade A for psoriasis 1
• Can remain at 50 mg twice weekly for patients requiring better disease control 1
• Generally less efficacious than adalimumab or infliximab (48% PASI-75 at 12 weeks vs 66-80% for others) 1

Certolizumab Pegol (Cimzia)

• Induction: 400 mg subcutaneous injection at weeks 0,2, and 4 (alternative: same dosing for patients <90 kg)
• Maintenance: 400 mg every 2 weeks OR 200 mg every 2 weeks 1
• Lower efficacy tier—suggested rather than recommended 3, 4

Golimumab (Simponi)

• Indication: Primarily for inflammatory bowel disease and rheumatoid arthritis
• Dosing: Weight-based for IBD; 50 mg monthly for RA 4
• Intermediate efficacy for ulcerative colitis 4

Key Clinical Decision Points

When choosing between TNF inhibitors:

1. First-line therapy for psoriasis: Adalimumab or infliximab are preferred over etanercept based on superior efficacy (80% vs 48% PASI-75 at 12 weeks) 1, 5

2. Psoriatic arthritis consideration: All three agents are Grade A recommendations, but adalimumab is specifically highlighted as first-line when arthropathy is present 2, 5

3. Inflammatory bowel disease: Infliximab and adalimumab are higher efficacy options; certolizumab is lower tier 3

4. Route preference matters:

   • Subcutaneous self-injection: Adalimumab, etanercept, certolizumab
   • IV infusion requiring clinic visits: Infliximab
   • Subcutaneous infliximab formulations now available with comparable efficacy 3, 4

Important Caveats

Biosimilars are equivalent: Biosimilars of infliximab, adalimumab, and ustekinumab can be considered therapeutically equivalent to originators 3, 4

Dose escalation strategies are evidence-based when patients show inadequate response 2:

• Adalimumab: 40 mg weekly (from every 2 weeks)
• Etanercept: 50 mg twice weekly (from once weekly)
• Infliximab: 5 mg/kg every 6 weeks or up to 10 mg/kg every 8 weeks

Combination therapy with methotrexate reduces immunogenicity and improves outcomes, particularly for monoclonal antibodies (adalimumab, infliximab) 1, 6

Contraindications apply to all TNF inhibitors: Active serious infections, tuberculosis (requires PPD testing), demyelinating diseases, NYHA class III-IV heart failure, and first-degree relatives with multiple sclerosis should avoid these agents 5

Monitoring requirements: Baseline tuberculosis screening is mandatory; hepatitis B screening in appropriate clinical settings; ongoing infection surveillance 5